THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED ACUTE MYOCARDIAL INFARCTION

  • Betül Çavuşoğlu Türker MD, Internal Medicine Clinic, Istanbul Haseki Health Training and Research Center, University of Health Sciences, Istanbul, Turkey
  • Süleyman Ahbab MD, Internal Medicine Clinic, Istanbul Haseki Health Training and Research Center, University of Health Sciences, Istanbul, Turkey
  • Fatih Türker MD, Internal Medicine Clinic, Arnavutkoy State Hospital, Istanbul, Turkey
  • Hayriye Esra Ataoğlu MD, Internal Medicine Clinic, Istanbul Haseki Health Training and Research Center, University of Health Sciences, Istanbul, Turkey
Keywords: Thrombotic Thrombocytopenic Purpura, myocardial infarction, acute renal injury

Abstract

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic microangiopathy. The central nervous system, kidneys, and myocard can be affected by TTP.

Case Presentation: A 47-year-old female patient with no chronic disease came to the emergency department presented with chest pain, blur in seeing. Electrocardiogram was performed and there was biphasic T wave pattern. Laboratory tests showed an elevation in white blood cell (14.103/mm3), decrease in thrombocyte (3.000/mm3). Blood urea nitrogen (BUN) was 129.3 mg/dl, serum creatinine was 1.87 mg/dl, lactate dehydrogenase (LDH) was 1581 U/l. Cardiac markers were elevated. These tests results revealed non ST-elevation myocardial infarction and acute renal injury. Antithrombotic agents were not applied because of thrombocytopenia. ADAMTS 13 activity was found lower than 0, 2 % and ADAMTS 13 antibodies were positive. Plasmapheresis was started to perform, immediately and repeated for ten days. After the treatment, hematologic parameters and LDH values came to normal ranges.

Conclusion: Thrombotic Thrombocytopenic Purpura (TTP) is a type of thrombotic microangiopathic anemia. If it is not diagnosed early, the mortality rate can be about 90%. Plasmapheresis should begin immediately.

Downloads

Download data is not yet available.

References

1. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of the thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3: 1432-6.
2. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004;407-423.
3. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-322.
4. Barrows BD, Teruya J. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch Pathol Lab Med. 2014;138(4):546-549.
How to Cite
1.
Betül Çavuşoğlu Türker, Süleyman Ahbab, Fatih Türker, Hayriye Esra Ataoğlu. THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED ACUTE MYOCARDIAL INFARCTION. Med. res. chronicles [Internet]. 1 [cited 2022Aug.18];5(3):183-5. Available from: https://medrech.com/index.php/medrech/article/view/303
Section
Case Report